{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:03:48Z","timestamp":1785927828695,"version":"3.56.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","award":["HO-17-18203"],"award-info":[{"award-number":["HO-17-18203"]}],"id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vaccine.2019.06.065","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T17:32:06Z","timestamp":1566322326000},"page":"5899-5908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer type"],"prefix":"10.1016","volume":"37","author":[{"given":"Elizabeth","family":"Packnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra E.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Novy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5587-2581","authenticated-orcid":false,"given":"Philip S.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Moore-Schiltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmina","family":"Hogea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.06.065_b0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4161\/hv.22302","article-title":"The changing epidemiology of meningococcal disease in North America 1945\u20132010","volume":"9","author":"Baccarini","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.06.065_b0010","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2019.06.065_b0015","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.06.065_b0020","unstructured":"Food and Drug Administration. October 29, 2014 Approval Letter - TRUMENBA. 2014. Available from: https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm421034.htm. Accessed: 1 January 2017."},{"key":"10.1016\/j.vaccine.2019.06.065_b0025","unstructured":"Food and Drug Administration. January 23, 2015 Approval Letter - BEXSERO. 2015. Available from: https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm431446.htm. Accessed: 1 January 2017."},{"key":"10.1016\/j.vaccine.2019.06.065_b0030","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged >\/=10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.06.065_b0035","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","article-title":"Updated recommendations for use of MenB-FHbp Serogroup B meningococcal vaccine - Advisory Committee on Immunization Practices, 2016","volume":"66","author":"Patton","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.06.065_b0040","unstructured":"MacNeil J. Considerations for Serogroup B Meningococcal (MenB) Vaccine Booster Doses in Persons at Increased Risk for Serogroup B Meningococcal Disease. 2017. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/58805\/cdc_58805_DS1.pdf. Accessed: 14 February, 2019."},{"key":"10.1016\/j.vaccine.2019.06.065_b0045","unstructured":"Kroger AT, Duchin J, V\u00e1zquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). 2017. Available from: https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/index.html. Accessed: 26 January, 2018."},{"key":"10.1016\/j.vaccine.2019.06.065_b0050","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.06.065_b0055","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12889-016-2845-z","article-title":"Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review","volume":"16","author":"Gallagher","year":"2016","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2019.06.065_b0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1071\/SH06008","article-title":"Predictors of completion of a hepatitis B vaccination schedule in attendees at a primary health care centre","volume":"4","author":"Macdonald","year":"2007","journal-title":"Sex Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:39Z","timestamp":1759401279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19308424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":12,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0264410X19308424"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer type","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}